ARCH-backed biotech emerges with $85M and a bold claim: A new human hormone can reverse a key effect of aging
The elderly patient’s muscles didn’t look right beneath the microscope.
He wasn’t just old. He had diabetic myopathy, a complication where muscles degrade faster than normal. The mitochondria die, fibers weaken, and the tissues become so broken up they resemble cracked Dust Bowl earth. “Like cottage cheese,” offers Russ Cox, a Genentech and Jazz Pharma alumn.
But now they looked — healthy. Mitochondria were firing. The fibers perked and stretched.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.